This resulted in the development of the recombinant humanized VEGFA-specific mAb bevacizumab, which was approved by the US FDA in 2004 for the first-line treatment of metastatic colorectal cancer, followed by the approval from the EMA and other regulatory authorities [249]. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.